{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:43:26Z","timestamp":1768916606596,"version":"3.49.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P26782"],"award-info":[{"award-number":["P26782"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"DOI":"10.3389\/fchem.2017.00104","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T04:21:25Z","timestamp":1513657285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacophore Modeling and in Silico\/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors"],"prefix":"10.3389","volume":"5","author":[{"given":"Muhammad","family":"Akram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Watcharee","family":"Waratchareeyakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Haupenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf W.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"B1","volume-title":"Pipeline Pilot","author":"Accelrys","year":"2011"},{"key":"B2","volume-title":"Discovery Studio. 4.0 Edn","year":"2015"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1016\/j.bmcl.2010.06.086","article-title":"The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-\u03b2-hydroxylase","volume":"20","author":"Adams","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1201\/b18799-7","article-title":"Pharmacophore modeling and pharmacophore-based virtual screening","volume-title":"In Silico Drug Discovery and Design","author":"Akram","year":"2015"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol. Dial. Trans."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0162-0134(01)00331-2","article-title":"Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2","volume":"87","author":"Belkina","year":"2001","journal-title":"J. Inorg. Biochem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1021\/ml4000589","article-title":"Aldosterone synthase inhibitors","volume":"4","author":"Blass","year":"","journal-title":"ACS Med. Chem. Lett."},{"key":"B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ml4000595","article-title":"Selective Cyp11B1 inhibitors for the treatment of cortisol dependent diseases","volume":"4","author":"Blass","year":"","journal-title":"ACS Med. Chem. Lett"},{"key":"B11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure","volume":"25","author":"Brilla","year":"2000","journal-title":"Herz"},{"key":"B13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.mce.2003.10.027","article-title":"Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11\u03b2-hydroxylase (CYP11B1) inhibitors: discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension","volume":"217","author":"Bureik","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"B15","volume-title":"ChemBioDraw Ultra. 14.0 Edn","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/bioinformatics\/bts249","article-title":"DecoyFinder: an easy-to-use python GUI application for building target-specific decoy sets","volume":"28","author":"Cereto-Massagu\u00e9","year":"2012","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/aps.2009.159","article-title":"Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets","volume":"30","author":"Chen","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/07435809509030460","article-title":"Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells","volume":"21","author":"Denner","year":"","journal-title":"Endocr. Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00008571-199504000-00005","article-title":"Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors","volume":"5","author":"Denner","year":"","journal-title":"Pharmacogenetics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001","volume":"482","author":"Devore","year":"2012","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/BF01711722","article-title":"Etomidate: a selective adrenocortical 11 beta-hydroxylase inhibitor","volume":"62","author":"Dorr","year":"1984","journal-title":"Klin. Wochenschr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0960-0760(02)00056-0","article-title":"Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells","volume":"81","author":"Ehmer","year":"2002","journal-title":"J. Steroid Biochem. Mol. Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0960-0760(00)00137-0","article-title":"Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli","volume":"75","author":"Ehmer","year":"2000","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1021\/jm400240r","article-title":"Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type","volume":"56","author":"Emmerich","year":"2013","journal-title":"J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1210\/jc.2002-021494","article-title":"Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure","volume":"88","author":"Faggiano","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1021\/jm400377z","article-title":"Design, synthesis, and structure\u2013activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors","volume":"56","author":"Ferlin","year":"2013","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1021\/jm301844q","article-title":"Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11\u03b2-hydroxylase inhibition","volume":"56","author":"Gobbi","year":"2013","journal-title":"J. Med. Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1021\/acs.jmedchem.5b01609","article-title":"Exploiting the chromone scaffold for the development of inhibitors of corticosteroid biosynthesis","volume":"59","author":"Gobbi","year":"2016","journal-title":"J. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/jbt.20174","article-title":"Mechanisms of cytochrome P450 substrate oxidation: minireview","volume":"21","author":"Guengerich","year":"2007","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0223-5234(03)00049-7","article-title":"Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis","volume":"38","author":"Hartmann","year":"2003","journal-title":"Eur. J. Med. Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1021\/ci300314k","article-title":"Conformer generation with OMEGA: learning from the data set and the analysis of failures","volume":"52","author":"Hawkins","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"B32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1021\/ci100031x","article-title":"Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and cambridge structural database","volume":"50","author":"Hawkins","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1021\/jm800377h","article-title":"Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity","volume":"51","author":"Heim","year":"2008","journal-title":"J. Med. Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/ml100283h","article-title":"Optimization of the first selective steroid-11\u03b2-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases","volume":"2","author":"Hille","year":"","journal-title":"ACS Med. Chem. Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/ml100071j","article-title":"First selective CYP11B1 inhibitors for the treatment of cortisol-dependent diseases","volume":"2","author":"Hille","year":"","journal-title":"ACS Med. Chem. Lett"},{"key":"B36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1021\/acsmedchemlett.5b00048","article-title":"Discovery of triazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys","volume":"6","author":"Hoyt","year":"2015","journal-title":"ACS Med. Chem. Lett"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1021\/jm3004637","article-title":"Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer","volume":"55","author":"Hu","year":"2012","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC \u2013 a free database of commercially available compounds for virtual screening","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0968-0004(99)01493-0","article-title":"Multiple physiological functions for multidrug transporter P-glycoprotein?","volume":"25","author":"Johnstone","year":"2000","journal-title":"Trends Biochem. Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0022-2836(95)80037-9","article-title":"Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation","volume":"245","author":"Jones","year":"1995","journal-title":"J. Mol. Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking1","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"19880","DOI":"10.3390\/molecules201219880","article-title":"Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases","volume":"20","author":"Kaserer","year":"2015","journal-title":"Molecules"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1073\/pnas.89.4.1458","article-title":"Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans","volume":"89","author":"Kawamoto","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1021\/ci500106z","article-title":"Pharmacophore modeling, virtual screening, and in vitro testing reveal haloperidol, eprazinone, and fenbutrazate as neurokinin receptors ligands","volume":"54","author":"Krautscheid","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"B45","doi-asserted-by":"publisher","first-page":"W200","DOI":"10.1093\/nar\/gkv353","article-title":"FAF-Drugs3: a web server for compound property calculation and chemical library design","volume":"43","author":"Lagorce","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0092-8674(01)00241-0","article-title":"Molecular mechanisms of human hypertension","volume":"104","author":"Lifton","year":"2001","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J. Mol. Cell. Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1021\/jm800683c","article-title":"Novel Aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach","volume":"51","author":"Lucas","year":"","journal-title":"J. Med. Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"8077","DOI":"10.1021\/jm800888q","article-title":"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives","volume":"51","author":"Lucas","year":"","journal-title":"J. Med. Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1021\/jm101470k","article-title":"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure\u2013activity and structure\u2013selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives","volume":"54","author":"Lucas","year":"2011","journal-title":"J. Med. Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","article-title":"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: in vivo evaluation in rodents and cynomolgus monkeys","volume":"58","author":"Martin","year":"2015","journal-title":"J. Med. Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1021\/ml400324c","article-title":"Discovery and in vivo evaluation of potent dual CYP11B2 (Aldosterone Synthase) and CYP11B1 inhibitors","volume":"4","author":"Meredith","year":"2013","journal-title":"ACS Med. Chem. Lett"},{"key":"B53","first-page":"647","article-title":"The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states","volume":"19","author":"Newell-Price","year":"1998","journal-title":"Endocr. Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1022308429992","article-title":"Medical therapy of Cushing's disease","volume":"5","author":"Nieman","year":"2002","journal-title":"Pituitary"},{"key":"B55","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1016\/S0021-9258(18)99077-0","article-title":"Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism","volume":"266","author":"Ogishima","year":"1991","journal-title":"J. Biol. Chem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7326\/0003-4819-89-1-128","article-title":"MEtyrapone is useful only as adjunctive therapy in cushing's disease","volume":"89","author":"Orth","year":"1978","journal-title":"Ann. Intern. Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1210\/jc.2002-021518","article-title":"Gender-related differences in the presentation and course of Cushing's disease","volume":"88","author":"Pecori Giraldi","year":"2003","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1021\/jm400484p","article-title":"Highly potent and selective nonsteroidal dual inhibitors of CYP17\/CYP11B2 for the treatment of prostate cancer to reduce risks of Cardiovascular diseases","volume":"56","author":"Pinto-Bazurco Mendieta","year":"2013","journal-title":"J. Med. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1006\/jmcc.1997.0612","article-title":"Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade","volume":"30","author":"Ramires","year":"1998","journal-title":"J. Mol. Cell. Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-connectivity fingerprints","volume":"50","author":"Rogers","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1021\/jm901356d","article-title":"Synthesis, biological evaluation, and molecular modeling of 1-Benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)","volume":"53","author":"Roumen","year":"2010","journal-title":"J. Med. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000063459","article-title":"Cushing's disease in childhood: presentation, investigation, treatment and long-term outcome","volume":"55","author":"Savage","year":"2001","journal-title":"Horm. Res."},{"key":"B64","first-page":"241","article-title":"The adrenal cortex and homeostasis","volume":"30","author":"Sayers","year":"1950","journal-title":"Phy. Rev"},{"key":"B65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/minf.200900071","article-title":"Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part I: model generation, validation and applicability in ethnopharmacology","volume":"29","author":"Schuster","year":"2010","journal-title":"Mol. Inform."},{"key":"B66","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1021\/ci200528d","article-title":"Recognizing pitfalls in virtual screening: a critical review","volume":"52","author":"Scior","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"B67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/14756369409020194","article-title":"Pyridyl substituted benzocycloalkenes: new inhibitors of 17\u03b1-Hydroxylase\/ 17,20-Lyase (P450 17\u03b1)","volume":"8","author":"Sergejew","year":"1994","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11906-000-0027-x","article-title":"Spironolactone in congestive heart failure","volume":"2","author":"Soberman","year":"2000","journal-title":"Curr. Hypertens. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1021\/jm101120u","article-title":"Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-\u03b1-Hydroxylase\/C17\u201320 lyase","volume":"54","author":"Stefanachi","year":"2011","journal-title":"J. Med. Chem"},{"key":"B70","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1210\/me.2012-1287","article-title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition","volume":"27","author":"Strushkevich","year":"2013","journal-title":"Mol. Endocrinol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1210\/jcem.83.3.4801","article-title":"Human CYP11B2 (Aldosterone Synthase) maps to chromosome 8q24.3","volume":"83","author":"Taymans","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B72","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrendo.2011.12","article-title":"Management of Cushing disease","volume":"7","author":"Tritos","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1021\/jm0492397","article-title":"Synthesis and evaluation of (Pyridylmethylene)tetrahydronaphthalenes\/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase","volume":"48","author":"Ulmschneider","year":"","journal-title":"J. Med. Chem"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1021\/jm049600p","article-title":"Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase","volume":"48","author":"Ulmschneider","year":"","journal-title":"J. Med. Chem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bmcl.2005.09.059","article-title":"Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2)","volume":"16","author":"Ulmschneider","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B76","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1021\/jm0503704","article-title":"Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis","volume":"48","author":"Voets","year":"2005","journal-title":"J. Med. Chem"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1021\/jm060055x","article-title":"Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis","volume":"49","author":"Voets","year":"2006","journal-title":"J. Med. Chem"},{"key":"B78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/minf.201300063","article-title":"Pharmacophore model refinement for 11\u03b2-hydroxysteroid dehydrogenase inhibitors: search for modulators of intracellular glucocorticoid concentrations","volume":"33","author":"Vuorinen","year":"2014","journal-title":"Mol. Inform"},{"key":"B79","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1021\/jm500140c","article-title":"Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors","volume":"57","author":"Yin","year":"2014","journal-title":"J. Med. Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/jm301408t","article-title":"Tetrahydropyrroloquinolinone type dual inhibitors of aromatase\/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks","volume":"56","author":"Yin","year":"2013","journal-title":"J. Med. Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1021\/jm3003872","article-title":"Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome","volume":"55","author":"Yin","year":"2012","journal-title":"J. Med. Chem"},{"key":"B83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1043-2760(00)00270-8","article-title":"Aldosterone and the heart","volume":"11","author":"Young","year":"2000","journal-title":"Trends Endocrinol. Metab"},{"key":"B84","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2174\/0929867323666160122114947","article-title":"Inhibitors of 11beta-Hydroxylase (CYP11B1) for treating diseases related to excess cortisol","volume":"23","author":"Zhu","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bmcl.2010.11.040","article-title":"N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)","volume":"21","author":"Zimmer","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fchem.2017.00104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T20:55:01Z","timestamp":1660164901000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fchem.2017.00104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":85,"alternative-id":["10.3389\/fchem.2017.00104"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2017.00104","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]},"article-number":"104"}}